• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重度血友病预防治疗的放射学评估

Radiologic evaluation of prophylaxis in severe haemophilia.

作者信息

Pettersson H, Nilsson I M, Hedner U, Noréhn K, Ahlberg A

出版信息

Acta Paediatr Scand. 1981 Jul;70(4):565-70. doi: 10.1111/j.1651-2227.1981.tb05741.x.

DOI:10.1111/j.1651-2227.1981.tb05741.x
PMID:6797235
Abstract

The effect of prophylactic treatment of severe haemophilia A and B was evaluated with a recently described radiologic score system for assessing the severity of arthropathy. The severity of the arthropathy was assessed in 50 patients with severe haemophilia receiving prophylaxis with factor VIII or IX (25--30 units factor VIII or IX/kg bodyweight at 4--7 day intervals), and in 9 in whom the condition was complicated by inhibitors and who were thus not receiving prophylaxis. The score values found in a recent investigation of the natural course of haemophilia served as controls in the evaluation of the effect of the prophylaxis. In the group with severe haemophilia receiving prophylaxis changes appeared only exceptionally in joints not affected already before the prophylaxis, and the course of the arthropathy and its severity according to age did not vary to any noteworthy extent from that in the control group with moderate haemophilia. In the cases complicated by inhibitors the joints were most often worse than those in the control group with severe haemophilia. It is concluded that prophylaxis has a considerable effect on the course of the arthropathy and the prophylaxis should be instituted at an early stage of the disease, when the joints are still unaffected.

摘要

采用最近描述的一种用于评估关节病严重程度的放射学评分系统,对重度甲型和乙型血友病的预防性治疗效果进行了评估。对50例接受凝血因子VIII或IX预防性治疗(每4 - 7天一次,剂量为25 - 30单位凝血因子VIII或IX/千克体重)的重度血友病患者以及9例因产生抑制剂而未接受预防性治疗且病情复杂的患者的关节病严重程度进行了评估。在评估预防性治疗效果时,将最近一项关于血友病自然病程研究中得到的评分值用作对照。在接受预防性治疗的重度血友病组中,仅在预防性治疗前未受影响的关节中偶尔出现变化,并且根据年龄的关节病病程及其严重程度与中度血友病对照组相比,没有显著差异。在有抑制剂并发症的病例中,关节状况通常比重度血友病对照组更差。得出的结论是,预防性治疗对关节病病程有显著影响,并且应在疾病早期关节仍未受影响时就开始进行预防性治疗。

相似文献

1
Radiologic evaluation of prophylaxis in severe haemophilia.重度血友病预防治疗的放射学评估
Acta Paediatr Scand. 1981 Jul;70(4):565-70. doi: 10.1111/j.1651-2227.1981.tb05741.x.
2
[Prevention of joint damage in hemophilic children with early prophylaxis].[早期预防对血友病患儿关节损伤的预防作用]
Orthopade. 1999 Apr;28(4):341-6. doi: 10.1007/PL00003616.
3
Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.在凝血障碍治疗中心接受初级预防治疗的严重 A 型或 B 型血友病儿童的矫形评估。
Haemophilia. 2011 Mar;17(2):228-32. doi: 10.1111/j.1365-2516.2010.02421.x. Epub 2010 Nov 11.
4
The overall effectiveness of prophylaxis in severe haemophilia.严重血友病预防治疗的总体疗效。
Haemophilia. 2003 May;9(3):272-8. doi: 10.1046/j.1365-2516.2003.00757.x.
5
Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.日本血友病定期替代治疗(预防)的现状
Haemophilia. 2009 Jan;15(1):78-82. doi: 10.1111/j.1365-2516.2008.01823.x. Epub 2008 Aug 12.
6
The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.血友病的治疗,包括预防治疗、持续输注和去氨加压素。
Baillieres Clin Haematol. 1996 Jun;9(2):259-71. doi: 10.1016/s0950-3536(96)80062-x.
7
The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.2663名血友病儿童和成人预防性治疗的应用:2006年加拿大全国血友病预防性治疗调查结果
Haemophilia. 2008 Sep;14(5):923-30. doi: 10.1111/j.1365-2516.2008.01810.x. Epub 2008 Jul 14.
8
Haemophilia prophylaxis in young patients--a long-term follow-up.年轻患者的血友病预防——长期随访
J Intern Med. 1997 May;241(5):395-400. doi: 10.1046/j.1365-2796.1997.130135000.x.
9
When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.血友病A和B患者的预防性治疗应何时开始?——德国的经验。
Haemophilia. 1998 Jul;4(4):413-7. doi: 10.1046/j.1365-2516.1998.440413.x.
10
Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.血友病患者的联合结局:预防方案依从性的重要性。
Haemophilia. 2009 Nov;15(6):1219-27. doi: 10.1111/j.1365-2516.2009.02077.x. Epub 2009 Jul 29.

引用本文的文献

1
Personalized Prophylaxis with myPKFiT: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients.基于 myPKFiT 的个体化预防治疗:血友病 A 患者真实世界的成本效果分析。
Medicina (Kaunas). 2023 Dec 24;60(1):34. doi: 10.3390/medicina60010034.
2
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.药代动力学参数驱动的结局模型预测,与抗血友病因子(重组)血浆/白蛋白游离方法相比,BAY 81-8973 在中国医疗环境中可减少出血事件。
BMC Med Res Methodol. 2022 Aug 5;22(1):215. doi: 10.1186/s12874-022-01659-w.
3
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China.
中国重度 A 型血友病成人患者药物代谢动力学指导预防与标准预防的成本效果分析。
Adv Ther. 2022 Aug;39(8):3777-3788. doi: 10.1007/s12325-022-02220-3. Epub 2022 Jun 30.
4
Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973).意大利甲型血友病患者的真实世界临床结局及凝血因子VIII替代治疗用量:八因子(拜科奇,BAY 81-8973)前后预防治疗的比较
J Clin Med. 2022 Jun 15;11(12):3434. doi: 10.3390/jcm11123434.
5
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.用于预防既往接受过治疗的 A 型或 B 型血友病患者出血和出血相关并发症的凝血因子浓缩物。
Cochrane Database Syst Rev. 2021 Aug 18;8(8):CD014201. doi: 10.1002/14651858.CD014201.
6
Impact of the HEAD-US Scoring System for Observing the Protective Effect of Prophylaxis in Hemophilia Patients: A Prospective, Multicenter, Observational Study.《HEAD-US 评分系统对血友病患者预防保护效果观察的影响:一项前瞻性、多中心、观察性研究》。
Turk J Haematol. 2021 Jun 1;38(2):101-110. doi: 10.4274/tjh.galenos.2021.2020.0717. Epub 2021 Jan 29.
7
Health-Related Quality of Life and Association With Arthropathy in Greek Patients with Hemophilia.希腊血友病患者的健康相关生活质量及其与关节病的关联
Clin Appl Thromb Hemost. 2018 Jul;24(5):815-821. doi: 10.1177/1076029617733041. Epub 2017 Oct 9.
8
Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.推进甲型血友病的个性化治疗:采用无血浆/无白蛋白方法制备的高级别抗血友病因子十年经验
Biologics. 2014 Apr 5;8:115-27. doi: 10.2147/BTT.S53456. eCollection 2014.
9
IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia.白细胞介素-6 受体拮抗剂作为辅助治疗与凝血因子替代疗法联合应用,以预防血友病患者出血相关关节病。
J Thromb Haemost. 2013 May;11(5):881-93. doi: 10.1111/jth.12176.
10
A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.一种评估预防性和按需治疗策略对重度血友病 A 长期疗效的建模方法。
Haematologica. 2011 May;96(5):738-43. doi: 10.3324/haematol.2010.029868. Epub 2011 Jan 27.